Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2315698 + GSK2398852
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
GSK2315698 + GSK2398852 is a combination investigational therapy for systemic amyloidosis consisting of miridesap (GSK2315698), a small molecule serum amyloid P component (SAP) depleter that removes SAP from the circulation, and dezamizumab (GSK2398852), a humanized IgG1 monoclonal antibody targeting SAP. SAP stabilizes amyloid fibrils that accumulate in organs in amyloidosis, protecting them from breakdown. The therapeutic aim is to first deplete circulating SAP using miridesap, then target residual SAP within amyloid deposits with dezamizumab, enabling immune-mediated clearance of amyloid from organs. The approach leverages complement activation and macrophage recruitment to remove the amyloid material. Both agents were developed by GSK for systemic amyloidosis. Clinical trials evaluated safety, pharmacokinetics, and effect on organ amyloid load, but development was discontinued after early phase studies[1][3][5][7].
- Other names
- miridesap + dezamizumab
02
Targets
SAP (Pentraxin 2)
Beyond the preview
Go deeper on GSK2315698 + GSK2398852.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2315698 + GSK2398852.